Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015697 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
A Phase 1 study of Recurrent or Metastatic Solid Tumors, sponsored by Daiichi Sankyo.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
- 20
- Study locations
NCT07015697 is a Phase 1 study of Recurrent or Metastatic Solid Tumors that is actively recruiting participants, run by Daiichi Sankyo. The registered enrollment target is 76 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT07015697, a Phase 1 study of Recurrent or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Daiichi Sankyo.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a dose escalation, and dose expansion study of T-DXd plus hyaluronidase administered subcutaneously, to assess the safety, tolerability, PK and efficacy of SC T-DXd plus hyaluronidase in participants with metastatic solid tumors.
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
Study Locations (20)
Other
- Research Site Saint - Herblain
- Research Site - Rennes
- Research Site - Chiba
- Research Site - Kanagawa
- Research Site - Tokyo
- Research Site - Tokyo
- Research Site - Tokyo
- Research Site - Seongnam-si
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Madrid
California
- Research Site - Newport Beach
Georgia
- Research Site - Atlanta
Nevada
- Research Site - Las Vegas
North Carolina
- Research Site - Charlotte
Ohio
- Research Site - Maumee
Tennessee
- Research Site - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-07-17 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07015697
The ClinicalTrials.gov registry entry for NCT07015697 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab Deruxtecan is the first listed.
NCT07015697 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT07015697 about?
NCT07015697 is a clinical study titled "A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors". This is a dose escalation, and dose expansion study of T-DXd plus hyaluronidase administered subcutaneously, to assess the safety, tolerability, PK and efficacy of SC T-DXd plus hyaluronidase in participants with metastatic solid tumors.
What is the current status of trial NCT07015697?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2025-07-17. Estimated completion is 2028-12-31.
What conditions does trial NCT07015697 study?
This clinical trial studies the following conditions: Recurrent or Metastatic Solid Tumors.
What interventions are being tested in trial NCT07015697?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT07015697?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015697 being conducted?
This trial has 20 study locations across California, Georgia, Nevada, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.